Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Prostate%20cancer Management



  • Based on the premise that it may be more beneficial to provide palliative therapy at the time when local or metastatic progression occurs, thereby maintaining quality of life
    • Also prompts a change in diagnostic tests when symptoms suggest disease progression
  • Management option for:
    • Patients who prefer not to undergo treatments
    • Elderly men or immunocompromised patients with comorbidities and/or poor prognostic features
    • Patients who will not benefit but will only incur harm from definitive treatments
  • Preferred for patients with very low-risk or low-risk prostate cancer with life expectancy of <10 years
  • Recommended for patients with non-metastatic castration-resistant prostate cancer (CRPC), with continued androgen deprivation therapy
  • Includes monitoring of prostate-specific antigen (PSA) and digital rectal examination (DRE) every 6 months


  • Potential harm from different unnecessary therapies may be avoided


  • Increases the risk for urinary retention and pathologic fracture

Active Surveillance

  • Watchful waiting while actively monitoring the disease course to be able to intervene when the disease progresses, delaying the potential side effects of treatments
  • Recommended for patients with very low-risk prostate cancer with life expectancy of 10-20 years
    • Preferred in patients with very low-risk prostate cancer with life expectancy of ≥20 years
  • Recommended for patients with low- and favorable intermediate-risk prostate cancer with life expectancy of ≥10 years
  • Criteria for the use of active surveillance include: Clinical stage T1c or T2a, grade group 1, <3 positive cores with ≤50% cancer involvement in any core, PSA <10 ng/mL, PSA density <0.15 ng/mL/g
    • Decision to use active surveillance should not be based solely on above criteria 
  • Treatment option for those with low-risk localized disease and candidates for radical prostatectomy or radiotherapy
    • May also be suggested to asymptomatic patients, elderly men, and those with comorbidities
  • Presence of any of the following pathology should prompt exclusion for active surveillance: Predominant ductal carcinoma, sarcomatoid carcinoma, small cell carcinoma, EPE or LVI in needle biopsy, perineal invasion


  • Initial: Multiparametric MRI (mpMRI) if not performed previously
  • 1st year: Monitoring of PSA every 6 months and DRE, prostate biopsy and mpMRI at 12 months
    • Repeat needle biopsy within 6 months from initial diagnosis is indicated for patients with <10 cores
    • Repeat biopsy may not be performed if the life expectancy is <10 years
  • 2nd-4th year: PSA monitoring every 3-6 months and DRE every 6-12 months
  • 5th year and yearly thereafter: PSA every 6 months and DRE every 12 months
  • PSA kinetics (doubling time and velocity) should be monitored all throughout active surveillance duration


  • Potential harm from different treatment modalities may be avoided
  • Patient may go back to their normal activities and may retain present quality of life
  • Smaller/undiagnosed malignancies will remain therapy-naive, thereby preventing future treatment resistance
  • Expenses may be reserved for more definitive treatments


  • Chance for early treatment and cure may be missed
  • High propensity for disease progression and metastasis
  • Tumor size may increase, making surgery and medical management more difficult
  • Preservation of function may be more difficult for more aggressive and bigger tumors
  • Increased anxiety due to untreated malignancy and uncertainty of disease progression
  • Intermittent monitoring with diagnostics and clinic visits are required

Follow Up

Local Recurrence

  • Initial PSA levels of ≥0.2 ng/mL and subsequent confirmatory levels of ≥0.2 ng/mL signifies biochemical recurrence
    • Biochemical recurrence can be categorized as either:
      • PSA level that fails to fall to undetectable levels post-radical prostatectomy
      • PSA level undetectable post-radical prostatectomy but with ≥2 subsequent laboratory results with detectable PSA level
      • Persistent or low PSA levels due to slow PSA metabolism or residual benign tissue
  • Endorectal ultrasound may be considered to rule out recurrence after radical prostatectomy

Follow-up Examinations

Prostate-Specific Antigen (PSA) Monitoring

  • PSA levels should be significantly lower after radical prostatectomy, radiation therapy, cryotherapy and other treatments
  • Should be done every 3-6 months x 5 years, then every 6-12 months x 5 years, then annually

Digital Rectal Exam (DRE)

  • Timing of DRE after EBRT or radical prostatectomy: Annual

Bone Scan

  • May be done if PSA levels rise after local therapy
  • Bone densitometry measurement by dual-energy x-ray absorptiometry (DEXA) scans should be obtained regularly especially in patients at high risk for skeletal side effects and for monitoring of treatment response to Denosumab or bisphosphonates

Computed Tomography (CT) Scan/Magnetic Resonance Imaging (MRI) Scan

  • May be considered if the following occurs after radical prostatectomy:
    • PSA levels still detectable
    • Previously undetectable PSA is suddenly detected
    • Recorded PSA increases in >2 PSA level examinations
    • Increasing PSA or positive DRE after radical prostatectomy
  • Spinal MRI to detect cord compression is recommended in CRPC patients with vertebral metastases and neurological symptoms
  • For patients without any evidence of metastases, the following imaging studies may be considered:
    • For further soft tissue and bone evaluation: C-11 choline PET/CT, PET/MRI, F-18 fluciclovine PET/CT or PET/MRI
    • For further bone evaluation: F-18 sodium fluoride PET/CT or PET/MRI

Gallium 68-PSMA PET/CT Scan  

  • Has comparable sensitivity and specificity with other FDA-approved imaging agents in detecting recurrences at lower PSA levels 
  • Has good sensitivity in prostate cancer restaging
  • Useful in identifying CRPC and in predicting response to therapy

Castration-Resistant Prostate Cancer (CRPC)

  • Recurrence or disease progression (clinical, radiographical or biochemical) despite medical or surgical castration
  • Criteria for defining CRPC:
    • PSA progression [PSA level >2 ng/mL, listed 3 consecutive increases 1 week apart, resulting in 25% increase over the nadir value]
    • Serum testosterone levels <50 ng/dL or <1.7 nmol/L
    • Anti-androgen withdrawal of >4-6 weeks

Salvage Treatments

  • Local salvage therapy options include salvage radical prostatectomy, HIFU, cryoablation and brachytherapy 
  • Salvage radiotherapy is a treatment option for patients with increasing PSA levels after radical prostatectomy and no presence of distant metastasis; should be given once biochemical recurrence has been confirmed
    • May consider hormone therapy if PSA is 0.20 ng/mL postoperatively
  • Salvage brachytherapy (permanent low dose-rate or temporary high dose-rate) may be considered in patients with confirmed local recurrence after EBRT or brachytherapy
  • Primary salvage EBRT with or without ADT may be considered in patients with PSA recurrence post-radical prostatectomy if without distant metastases 
  • Salvage radical prostatectomy may be used for patients with local recurrence after radiotherapy or cryotherapy
  • Salvage ADT alone may be considered in patients with proven or high suspicion of metastasis, symptomatic local disease, or biochemical relapse with rapid PSA doubling time


Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).